Brain Storm
Welcome to BrainStorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a leading  developer of  stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury

 

The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company’s NurOwn™ therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms.
  
BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.
 

 

 

News
March 23, 2009
Brainstorm Cell Therapeutics Elects Malcolm S. Taub to its Board of Directors

March 4, 2009 -
BrainStorm’s Stem Cell Technology demonstrates efficacy in an experimental model of Parkinson’s disease- Paper published in "Stem Cells and Development"

February 09, 2009
BrainStorm Cell Therapeutics’ consultant to assist with final regulatory preparations towards clinical trials for ALS patients based on stem cells treatment

November 03, 2008
BrainStorm Cell Therapeutics Inc. to Present at Rodman Renshaw Healthcare Conference

September 02, 2008
World Renowned ALS Expert from Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board

July 22, 2008
New paper published in "Stem Cells” reporting in-vivo migration ability of Brainstorm cell Therapeutics' NTF cells

July 07, 2008
BrainStorm Cell Therapeutics and Rutgers University study shows that Transplanting NTF Cells improves the recovery of Spinal Cord injury rat model

June 16, 2008
Israeli Government Chief Scientist Office Awards $870,000 Grant to BrainStorm Cell Therapeutics for the second consecutive year

May 29, 2008
BrainStorm Cell Therapeutics NTF Cells Shows Significant Advantage in Pre-Clinical Study for Parkinson’s Disease

May 27, 2008
Brainstorm Cell Therapeutics Chief Scientist, Dr. Daniel Offen, To Present Results from New Parkinson’s Study at International Stem Cell Meeting in Tel Aviv

May 15, 2008
World renowned Spinal Cord specialist, Dr. Martin Grumet, from Rutgers University, to visit BrainStorm Cell Therapeutics’ headquarters to discuss experiment results

March 31, 2008
BrainStorm Cell Therapeutics Opens New Onsite Animal House

November 27, 2007
BrainStorm Cell Therapeutics Adult Stem Cell Approach more relevant than Embryonic SC Therapies

MS - Multiple Sclerosis
Oligodendrocyte
PD-Parkinson's Disease
Neuron
ALS - Amyotrophic Lateral ...
Astrocyte